MDBK cells are responsive to PPAR agonists and serve as a promising in vitro model to evaluate PPAR activation and fatty acid potency in bovine cells.
Supports MDBK cells as bovine in vitro PPAR model; leaves open in vivo translation to dairy cattle metabolism.
The peroxisome proliferator-activated receptors (PPAR) are critical for lipid metabolism, and many fatty acids are PPAR agonists. Madin-Darby bovine kidney (MDBK) cells were tested as an in vitro bovine model for PPAR activation, and preliminary evaluation of the effect of fatty acids on bovine PPAR was performed. Cells were treated with Wy-14643 (WY, specific PPARalpha agonist) and rosiglitazone (ROSI, specific PPARgamma agonist). The gene expression of specific PPARalpha-responsive genes such as carnitine palmitoyl transferase-1 (CPT1A) and acetyl coenzyme A oxidase (ACOX1) and of PPARgamma-responsive gene lipoprotein lipase (LPL) were analyzed using real-time reverse transcription PCR. It was found that CPT1A exhibited a significant increase in cells treated with WY, whereas the ACOX1 gene expression was not altered. The LPL gene expression showed an increase in response to ROSI. Interestingly, LPL was almost undetectable in MDBK cells not treated with ROSI. The potency of different fatty acids in activating PPARalpha as assessed by CPT1A mRNA abundance in MDBK cells was also tested. The mRNA of CPT1A (2.5- to 1.4-fold) was significantly increased by fatty acids in the order of palmitate > linolenate > linoleate > conjugated linoleate, and oleate. The results demonstrated MDBK cells to be responsive to PPAR agonists and thus a promising model to evaluate the role of PPAR in bovine cells. In addition, fatty acids were proven to have a different potency in modulating expression of CPT1A through PPARalpha.
No takes yet. Share an insight, caveat, or question.
Bionaz et al. (2008) studied In vitro model for PPAR activation. Wy-14643, rosiglitazone, and fatty acids vs. Untreated cells was evaluated on Gene expression of CPT1A, ACOX1, and LPL (2.5- to 1.4-fold increase for CPT1A).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: